Q1 2022 Results

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Our pipeline projects at a glance Innovative medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular, Renal, Metabolism Others Ophthalmology Respiratory & Allergy Global Health Biosimilars 37 Investor Relations | Q1 2022 Results Appendix Innovation: Clinical trials References Abbreviations Phase 1/2 104 Phase 3 Registration Total 50 6 160 25 20 2 47 20 LO 22652 7 3 30 7 0 33 5 0 11 6 0 11 5 1 28 6 1 0 7 8 3 0 11 8 1 1 10 0 2 2 2 Total 104 52 6 162 NOVARTIS | Reimagining Medicine

View entire presentation